OMICS is widely employed for searching diagnostic biomarker of neurology diseases. Some applications are:
Dedicated platforms can be employed to find predictive and diagnostic biomarkers.
However much efforts should be done to create biomarker database specific for neurological degenerative diseases and related to infection affecting the nervous system. Ideal database should connect the biomarkers to the disease cause like infection or metabolic disfunction. It should also provide indications on the better registered protocols and therapies to be used on the basis of biochemical evaluation. Some molecular biomarker database are follow reported:
We have a project to join different molecular database in order to obtain a high efficient tool to be used for diagnosis, disease progression monitoring and therapy purposes. We will keep you updated.
ISB has activated a service for the analysis of the follow steroids in serum and plasma:
Contact us for further informations.
Pharmaceutical products analysis require the use of OMICS science. In fact they are able to predict:
1) The origin of product not conformity;
2) The product alteration.
It is so possible to obtain important information at molecular level to be used for product quality control and to find production process malfunction.
To obtain this results OMICS provide the full pictures of the pharmaceutical product molecular composition and use selective database to find the product not conformity or alteration.
Dedicated simplified platforms can be used to achieve this result.
The evolution of proteomics has been fast especially in the last two years. The main reason of this is related to the bioinformatics. Strong innovations has been observed starting from 2004 to nowadays. Basically, after the development of high evoluted algorithms it is the time of database innovation. The combination of evoluted algorithms and databases open the way for the follow applications:
- Clinical Research
- Food Traceability.
- Nutraceutical Sector.
- Pharmaceutical Industry.
- Cosmetic industry.
Some software that make the difference in proteomics field are:
- xTandem for optimized database search
- OpenMS a programable platform for all kind of proteomics data elaborations
- SANIST data analysis a simplified platform for protein quantitative and qualitative analysis based on the European standards.
All these tools are based on optimized join of high accurate algorithms and high quality databases.
Proteomics and metabolomics are both important for precision medicine. In fact, metabolomics makes possible to detect metabolic disfunction and proteomics permits to connect them to enzymatic altered ways.
A good precision medicine strategy is:
- Untarget or target search of altered metabolite in urine.
- Bioinformatics studies to connect metabolite with enzymatic disfunction.
- Target study of the involved enzyme in serum sample.
Urine and serum are suggested because they are the most analyzed matrices in clinical lab. Thus the clinical protocols are just ready to collect them.
The critical task is the bioinformatics step that should be adapted to the clinical laboratory routine. In this context analytical platforms that standardize and semplify data analysis are needed.
We strongly thinks that in the next 5 years many clinical centers will be provided with evoluted analytical platform that will strongly enhance the power of precision medicine.
Proteomics is a consolidated science used in the research field. Even in the clinical fields its applications are growing. The clinical applications are mainly focalized on:
- Quantitation dosage of antibodies or other proteins of clinical interest;
- Determination of aminoacidic mutations and correlation with the diseases (e.g: determination of Hemoglobin modifications).
Concerning the point 1, dosages can be performed using different technologies (e.g.: ELISA, RIA, Mass Spectrometry). ELISA kits dominate the market thanks to the high throughput performance and the simple sample preparation procedure. Mass Spectrometry (MS) technolgy require high technical competence but the dosage methods development is easier with respect to the other approaches. MS provide, also, higher quantitation accuracy and precision.
MS is particularly suited for the point 2. Identification of the protein mutation can be obtained using certified database containing the protein sequences. One of the most used is Uniprot. This is a global protein database. The proteins are classified and scheduled on the bases of the taxonomy. More selective databases are present for specific clinical diagnosis.
MS platform equiped with sample preparation kits, mass spectrometric device and dedicated data elaboration system have been developed, in the recent years. The advent of these platforms will potentialy leads strongly increase MS clinical applications.
Alterations of phospholipids (PLs) profiles have been may be involved in the onset and evolution of cancer.
Mass spectrometry is a widelly employed technology for phospholipids detection and quanitation. Lipidomic analysis has proven to be usefull in breast cancer diagnosis. Specific PL profiles are usually associated with the degree of tumor malignancy. The study of brest cancer cell lines has shown correlation in phosphatidylethanolamine (PE) concentration with respect to total amount of PLs and the cell status: PE was highest in non-malignant cells while phosphatidic acid was present with highest relative abundance in metastatic cells. PE and its methabolim can so be usefull for study cancer prograssion.
An interesting overview about this argument and on PLs profile associated to cancer progression is disclosed in the follow pubblication: link.
ISB will propose, in about two month a service for untarghet and target plasma lipidomics analysis based on SANIST technology.
A target low polar serum and plasma steroids panel will be provided due to their interest in the research field. Steroids are usually related with different diseases and are very difficult to quantitate mainly due to their low amount in biological matrix . The steroids panel that will be:
For further informations write us through the contact form.
Metabolomics, proteomics and genomics could be integrated with genomics an bioinformatics so to obtain a systemic approach for disease diagnosis and treatment. This strategy is particular important in the case of rare diseases. In these pathologies the technologies can lead to obtain the follow informations:
- Gene expression potentially associated with the disease;
- Epigenetic disease correlation;
- Proteomics expression correlation;
- Metabolomics expression correlation.
These informations make possible to find the potential disease cause (e.g.: intestinal disbiosis) and to associate it to the enzymatic funtional disfunction. The knowledge of these data provide useful indications to be used for personalized and precision medicine therapy.
Proteomics is becaming a powerful tool for personalized medicine together with genomics and other omics science.
The advent of mass spectrometry and of standardized technologies like SANIST make possible to develop an high amount of applications to be used for clinical diagnosis and therapy.
Here we propose an interesting review on proteomics in personalized medicine. Click here to read.